PL445683A1 - Zastosowanie oksysterolu 7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego - Google Patents

Zastosowanie oksysterolu 7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego

Info

Publication number
PL445683A1
PL445683A1 PL445683A PL44568323A PL445683A1 PL 445683 A1 PL445683 A1 PL 445683A1 PL 445683 A PL445683 A PL 445683A PL 44568323 A PL44568323 A PL 44568323A PL 445683 A1 PL445683 A1 PL 445683A1
Authority
PL
Poland
Prior art keywords
oxysterol
autoimmune
inflammatory
modulation
treatment
Prior art date
Application number
PL445683A
Other languages
English (en)
Other versions
PL249180B1 (pl
Inventor
Aleksandra RUTKOWSKA
Bartosz Karaszewski
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL445683A priority Critical patent/PL249180B1/pl
Priority to EP24191137.9A priority patent/EP4497440A1/en
Publication of PL445683A1 publication Critical patent/PL445683A1/pl
Publication of PL249180B1 publication Critical patent/PL249180B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Wynalazek dotyczy oksysterolu CF3-7α,25OHC o działaniu modulującym układ immunologiczny oraz stymulującym odbudowę mieliny do zastosowania w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego, zwłaszcza stwardnienia rozsianego.
PL445683A 2023-07-27 2023-07-27 Zastosowanie oksysterolu 7-trifluorometylo-7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego PL249180B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL445683A PL249180B1 (pl) 2023-07-27 2023-07-27 Zastosowanie oksysterolu 7-trifluorometylo-7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego
EP24191137.9A EP4497440A1 (en) 2023-07-27 2024-07-26 Use of 7-trifluoromethyl-7alpha,25-dihydroxycholesterol in the treatment and modulation of autoimmune and inflammatory diseases of the nervous system and neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445683A PL249180B1 (pl) 2023-07-27 2023-07-27 Zastosowanie oksysterolu 7-trifluorometylo-7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego

Publications (2)

Publication Number Publication Date
PL445683A1 true PL445683A1 (pl) 2025-02-03
PL249180B1 PL249180B1 (pl) 2026-03-09

Family

ID=92801248

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445683A PL249180B1 (pl) 2023-07-27 2023-07-27 Zastosowanie oksysterolu 7-trifluorometylo-7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego

Country Status (2)

Country Link
EP (1) EP4497440A1 (pl)
PL (1) PL249180B1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11919895B2 (en) * 2019-10-25 2024-03-05 Saint Louis University GPR183 antagonists for the treatment of pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENG X. EL AL.: "Bioorg Med Chem Lett. 2016; 26(20): 4888-4891", FLUORO ANALOGS OF BIOACTIVE OXY-STEROLS: SYNTHESIS OF AN EBI2 AGONIST WITH ENHANCED METABOLIC STABILITY. *
KLEJBOR I. ET AL.: "Eur J Neurosci. 2021; 54(3): 5173-5188", EBI2 IS EXPRESSED IN GLIAL CELLS IN MULTIPLE SCLEROSIS LESIONS, AND ITS KNOCK-OUT MODULATES REMYELINATION IN THE CUPRIZONE MODEL. *
RUTKOWSKA A. ET AL.: "J Neuroinflammation. 2017; 14(1): 250", EBI2 RECEPTOR REGULATES MYELIN DEVELOPMENT AND INHIBITS LPC-INDUCED DEMYELINATION. *
VELASCO-ESTEVEZ M. ET AL.: "Int J Mol Sci. 2021; 22(9):4342", EBI2 IS TEMPORARILY UPREGULATED IN MO3.13 OLIGODENDRO-CYTES DURING MATURATION AND REGULATES REMYELINATION IN THE ORGANOTYPIC CEREBELLAR SLICE MODEL. *

Also Published As

Publication number Publication date
EP4497440A1 (en) 2025-01-29
PL249180B1 (pl) 2026-03-09

Similar Documents

Publication Publication Date Title
MX2019012144A (es) Arn para tratamiento de enfermedades autoinmunitarias.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
WO2019094724A8 (en) Ganaxolone for use in treating genetic epileptic disorders
MX2022006072A (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2023004369A (es) Compuestos triciclicos para degradar neosustratos para terapia medica.
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
JOP20200290A1 (ar) تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة
UY33206A (es) Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4
PH12020551619A1 (en) Anti-trem-1 antibodies and uses thereof
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PH12023552792A1 (en) Combination therapies for the treatment of cancer
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
BR112021018918A2 (pt) Compostos e composições como moduladores de sinalização de tlr
PL445683A1 (pl) Zastosowanie oksysterolu 7α,25-dihydroksycholesterolu w leczeniu i modulowaniu chorób autoimmunologicznych, zapalnych i demielinizacyjnych ośrodkowego układu nerwowego
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112019008241A2 (pt) tratamento do prurigo nodular